Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: A clinical and immunohistochemical analysis

Spine

Volumn 37, Issue 13, 2012, Pages

  Froehlich, Elke Verena ^a   Scheipl, Susanne ^a   Lazàry, Aron ^b   Varga, Peter Pal ^b   Schmid, Christoph ^a   Stammberger, Heinz ^a   Beham, Alfred ^a   Bodo, Koppany ^a   Schroettner, Heribert ^a   Quehenberger, Franz ^a   Windhager, Reinhard ^a   Liegl, Bernadette ^a   Leithner, Andreas ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b National Centre for Spinal Disorders   (Hungary)

Author keywords

age ; brachyury; chordoma; COX 2; ezrin; immunohistochemistry; location ; MMP 9; volume dependent survival

Indexed keywords

CYCLOOXYGENASE 2; CYTOKERATIN; EPITHELIAL MEMBRANE ANTIGEN; EZRIN; GELATINASE B; PROTEIN S 100; VIMENTIN;

ADULT; AGE; AGED; ARTICLE; CALCULATION; CANCER SURVIVAL; CHORDOMA; CLINICAL ARTICLE; CLINICAL EVALUATION; COCCYGEAL BONE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RETROSPECTIVE STUDY; SACRUM; SKULL BASE; SPINE; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; CHORDOMA; CYCLOOXYGENASE 2; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; HUNGARY; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SKULL NEOPLASMS; SPINAL NEOPLASMS; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84862213965     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e31824782e1     Document Type: Article

References (49)

1. Mertens F, Mirra JM, Della Rocca C, et al., eds. Chordoma. Lyon : WHO, IARC Press; 2002 : 315-17.
2. MacMaster MS, Goldstein AM, Bromley CM, et al. Chordoma: Incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12 : 1-11.
3. Bergh P, Kingblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine. A study of 39 patients. Cancer 2000; 88 : 2122-34.
4. Moojen WA, Vleggeert-Lankamp CL, Krol AD, et al. Long-term results: Adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable. Spine 2011; 36 : E656-61.
5. McPherson CM, Suki D, McCutcheon IE, et al. Metastatic disease from spinal chordoma: A 10-year experience. J Neurosurg Spine 2006; 5 : 277-80.
6. Ruggieri P, Angelini A, Ussia G, et al. Surgical margins and local control in resection of sacral chordomas. Clin Orthop Relat Res 2010; 468 : 2939-47.
7. Campanacci M, Enneking WF, eds. Bone and Soft Tissue Tumors. Wien, New York : Springer Verlag; 1999 : 689-98.
8. Park L, Delaney TF, Liebsch NJ, et al. Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006; 65 : 1514-21.
9. Boriani S, Bandiera S, Biagini R, et al. Chordoma of the mobile spine: Fifty years of experience. Spine 2006; 31 : 493-503.
10. Azzarelli A, Quagliuolo V, Cerasoli S, et al. Chordoma: Natural history and treatment results in 33 cases. J Surg Oncol 1988; 37 : 185-91.
11. Sundaresan N, Galicich J, Chu F, et al. Spinal chordomas. J Neurosurg 1979; 50 : 312-9.
12. Jian BJ, Bloch OG, Yang I, et al. Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma. J Neurooncol 2010; 98 : 101-8.
13. Conlon FL, Wright CV, Robertson EJ. Effects of the TWis mutation on notochord formation and mesodermal patterning. Mech Dev 1995; 49 : 201-9.
14. Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: A marker that distinguishes chordoma from mixed tumor/myoepithelioma/ parachordoma in soft tissue. Am J Surg Pathol 2008; 32 : 572-80.
15. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006; 209 : 157-65.
16. O'Donnell P, Tirabosco R, Vujovic S, et al. Diagnosing an extraaxial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation. Skeletal Radiol 2007; 36 : 59-65.
17. Ferrari S, Zanella L, Alberghini M, et al. Prognostic signifi cance of immunohistochemical expression of ezrin in non-metastatic highgrade osteosarcoma. Pediatr Blood Cancer 2008; 50 : 752-6.
18. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10 : 182-6.
19. Kim MS, Song WS, Cho WH, et al. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007; 459 : 229-36.
20. Salas S, Bartoli C, Deville JL, et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch 2007; 451 : 999-1007.
21. Weng WH, Ahlen J, Astrom K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 2005; 11 : 6198-204.
22. Geiger KD, Stoldt P, Schlote W, et al. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 2000; 157 : 1785-93.
23. Ilmonen S, Vaheri A, Asko-Seljavaara S, et al. Ezrin in primary cutaneous melanoma. Mod Pathol 2005; 18 : 503-10.
24. Bretscher A. Regulation of cortical structure by the ezrin-radixinmoesin protein family. Curr Opin Cell Biol 1999; 11 : 109-16.
25. Curto M, McClatchey AI. Ezrina metastatic detERMinant? Cancer Cell 2004; 5 : 113-4.
26. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004; 10 : 201-4.
27. Bjornland K, Flatmark K, Pettersen S, et al. Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 2005; 127 : 151-6.
28. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and-9) and their inhibitors (TIMP-1 and-2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003; 6 : 217-22.
29. Gaffney DK, Holden J, Davis M, et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49 : 1213-7.
30. Gaffney DK, Holden J, Zempolich K, et al. Elevated COX-2 expression in cervical carcinoma: Reduced cause-specific survival and pelvic control. Am J Clin Oncol 2001; 24 : 443-6.
31. Kawashima A, Okada Y, Nakanishi I, et al. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol 1997; 142 : 129-37.
32. Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 2009; 21 : 1323-33.
33. Sugita H, Osaka S, Toriyama M, et al. Correlation between the histological grade of chondrosarcoma and the expression of MMPs, ADAMTSs and TIMPs. Anticancer Res 2004; 24 : 4079-84.
34. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83 : 324-8.
35. Ueda Y, Imai K, Tsuchiya H, et al. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of humangiant cell tumor of bone and is associated with vascular invasion. Am J Pathol 1996; 148 : 611-22.
36. Naka T, Kuester D, Boltze C, et al. Expression of matrix metalloproteinases-1,-2, and-9; tissue inhibitors of matrix metalloproteinases-1 and-2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol 2008; 39 : 217-23.
37. Juuti A, Louhimo J, Nordling S, et al. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006; 59 : 382-6.
38. Kawabe A, Shimada Y, Uchida S, et al. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 2002; 62 : 46-54.
39. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153 : 106-20.
40. Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; 204 : 9-24.
41. Park HR, Jung WW, Bacchini P, et al. Ezrin in osteosarcoma: Comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract 2006; 202 : 509-15.
42. Kim MS, Cho WH, Song WS, et al. Prognostic signifi cance of ezrin expression in pleomorphic malignant fi brous histiocytoma. Anticancer Res. 2007; 27 : 1171-8.
43. Stetler-Stevenson WG. Type I collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9 : 289-303.
44. Benassi MS, Gamberi G, Magagnoli G, et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 2001; 12 : 75-80.
45. Rahmah NN, Sakai K, Nakayama J, et al. Reversion-inducing cysteine-rich protein with Kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas. Neurosurg Rev 2010; 33 : 167-73; discussion 173.
46. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105 : 1589-94.
47. Fosslien E. Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001; 31 : 325-48.
48. Fasig JH, Dupont WD, Olson SJ, et al. Steroid hormone receptor and COX-2 expression in chordoma. Am J Clin Pathol 2007; 128 : 375-81.
49. Daugaard S, Christensen LH, Hogdall E. Markers aiding the diagnosis of chondroid tumors: An immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS 2009; 117 : 518-25.